

Electronic Supporting Information

3D-printed devices for multiplexed semi-quantitative competitive lateral flow immunoassays

Guodong Tong¹, Kazushi Misawa¹, Purim Jarujamrus^{1,2,3}, Yuki Hiruta¹, Daniel Citterio¹

¹ Department of Applied Chemistry, Faculty of Science and Technology, Keio University, 3-14-1 Hiyoshi, Kohoku ward, Yokohama, Kanagawa 223-8522, Japan.

² Department of Chemistry and Center of Excellence for Innovation in Chemistry, Faculty of Science, Ubon Ratchathani University, Ubon Ratchathani 34190, Thailand.

³ Nanomaterials Science, Sensors & Catalysis for Problem-Based Projects, Faculty of Science, Ubon Ratchathani University, Ubon Ratchathani 34190, Thailand.

Table of Contents

1. Design of device type B.....	S3
2. Details and layouts of all pads	S4
3. Details and design sketches of 3D models.....	S5
4. Design of cap for device type B and P.....	S8
5. Definition of Δ Gray value.....	S9
6. Results of text-displaying assay.....	S10
7. Composition of artificial urine.....	S11
8. Relationship between combined ratio and initial concentration of Ab and Ag.....	S12

1. Design of device type B




Fig. S1 Design of device type B with 8 LFIA lanes for plastic-backed nitrocellulose membranes; blue/red arrows represent the sample liquid flow path on the example of a single LFIA lane.

2. Details and layouts of all pads







Fig. S2 Details of size and arrangement of all components used for LFIA preparation in each lane: (a) cutting dimensions of all pads (TP: transfer pad); pad arrangement for device types B (b) and P (c); all numerals indicate dimensions in mm.

3. Details and design sketches of 3D models









Fig. S3 Sketches for Lid (a, e), Container (b, f), Cap for device P (c, g), and Cap for device B (d, h); all numerals indicate dimensions in mm.

4. Design of cap for device type B and P





Fig. S4 Details of cap supporting protrusion sections for device type B (a) and type P (b); all numerals indicate dimensions in mm.

5. Definition of Δ Gray value



$$\Delta\text{Gray value} = (\textcircled{1} + \textcircled{3}) / 2 - \textcircled{2}$$

Fig. S5 Definition and calculation method of the Δ Gray value used for quantitative analysis of test line color intensities.

6. Original scanned picture for text-displaying semiquantitative detection





Fig. S6 Unmodified color scans showing text-displaying results for the semi-quantitative detection of (A) caffeine = 0 ng/mL and acetaminophen = 0 ng/mL, (B) caffeine = 4 ng/mL and acetaminophen = 4 ng/mL, (C) caffeine = 10 ng/mL and acetaminophen = 8 ng/mL, (D) caffeine = 175 ng/mL and acetaminophen = 12 ng/mL in artificial urine samples; all experiments have been performed in triplicate with the results of 3 devices shown in each row.

7. Composition of artificial urine

Table S1 Composition of artificial urine samples

Chemicals	Conc.(mM)
Lactic Acid	1.1
Citric Acid	2
Sodium Bicarbonate	25
Urea	170
Calcium Chloride	2.5
Sodium Chloride	90
Magnesium Sulfate	2
Sodium Sulfate	10
Potassium Dihydrogen Phosphate	7
Dipotassium Hydrogen Phosphate	7
Ammonium Chloride	25
Uric Acid	0.4
Creatinine	7
BSA	1(g/L)

8. Relationship between combined ratio and initial concentration of Ab and Ag



$$K_a = \frac{C}{[Ab][Ag]} = \frac{C}{([Ab]_0 - C)([Ag]_0 - C)}$$

$$C^2 - \left(\frac{1}{K_a} + [Ab]_0 + [Ag]_0 \right) C + [Ab]_0 [Ag]_0 = 0$$

$$C = \frac{\left(\frac{1}{K_a} + [Ab]_0 + [Ag]_0 \right) - \sqrt{\left(\frac{1}{K_a} + [Ab]_0 + [Ag]_0 \right)^2 - 4[Ab]_0 [Ag]_0}}{2}$$

- K_a : Affinity constant($\approx 10^{12}$)
- $[Ab]$: Antibody conc.
- $[Ag]$: Antigen conc.
- $[Ab-Ag]$: Complex conc.(C)
- $[Ag]_0$: Initial antigen conc.
- $[Ab]_0$: Initial antibody conc.
- **Combined ratio[%] = $C / [Ab]_0 \times 100\%$**

Eq. S1 Relationship between immunocomplex and the concentration of antibody or antigen